Equity Incentive Plans (Tables)

9 Months Ended

Sep. 30, 2018

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

A summary of the status of the Company’s option plans as of September 30, 2018 and changes during the period then ended is presented below:

	Nine months ended September 30, 2018
	Unaudited
	Number of options			Weighted average exercise price
Outstanding at beginning of year		14,806,027		$	10.64
Granted		2,424,058			23.40
Exercised		(2,486,026	)		6.77
Forfeited and cancelled		(178,093	)		14.68
Outstanding as of September 30, 2018		14,565,966		$	13.37

Exercisable options		5,885,994		$	10.42

Schedule of RSU's

A summary of the status of the Company’s RSUs as of September 30, 2018 and changes during the period then ended is presented below:

	Nine months ended September 30, 2018
	Unaudited
	Number of RSUs			Weighted average grant date fair value price
Unvested at beginning of year		1,651,219		$	9.66
Granted		521,305			23.08
Vested		(550,418	)		9.66
Forfeited and cancelled		(15,220	)		15.28
Unvested as of September 30, 2018		1,606,886		$	13.96

Schedule of Fair Value Assumptions Used for All Equity Based Awards Estimated Using Black-Scholes Option Pricing Model

The fair value of share-based awards was estimated using the Black-Scholes model for all equity grants. For market condition awards, the Company also applied the Monte-Carlo simulation model, with the following underlying assumptions:

	Nine months ended September 30,		Year ended December 31,
	2018	2017	2017
	Unaudited		Audited
Stock Option Plans
Expected term (years)	5.50-6.25	5.50-6.25	5.50-6.25
Expected volatility	52%-55%	57%-59%	57%-59%
Risk-free interest rate	2.70%-2.89%	1.97%-2.23%	1.97%-2.23%
Dividend yield	0.00%	0.00%	0.00%
ESPP
Expected term (years)	0.50	0.50	0.50
Expected volatility	45%-53%	76%-82%	76%-82%
Risk-free interest rate	1.61%-2.14%	0.62%-1.13%	0.62%-1.13%
Dividend yield	0.00%	0.00%	0.00%

Schedule of Non-cash Share-based Compensation Expense Related to Company's Equity-Based Awards

The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three and nine months ended September 30, 2018 and 2017 and the year ended December 31, 2017 was:

	Three months ended September 30,				Nine months ended September 30,				Year ended December 31,
	2018		2017		2018		2017		2017
	Unaudited				Unaudited				Audited
Cost of revenues	$	464	$	79	$	891	$	353	$	467
Research, development and clinical trials		1,223		972		3,415		2,645		3,587
Sales and marketing		1,979		1,874		5,309		4,264		3,784
General and administrative		6,813		5,704		19,590		13,498		19,278
Total share-based compensation expense	$	10,479	$	8,629	$	29,205	$	20,760	$	27,116